Tango Therapeutics Appoints Robert Azelby to Board as It Advances PRMT5 Inhibitor
Tango Therapeutics (NASDAQ: TNGX) appointed Robert Azelby, a biopharma executive with over 30 years of experience in oncology commercialization, corporate strategy, company building, and board governance, to its board of directors. The appointment comes as Tango advances vopimetostat, an investigational PRMT5 inhibitor, toward potential late-stage development for pancreatic cancer.
Tango Therapeutics (NASDAQ: ) appointed Robert Azelby to its board of directors on June 22, as the clinical-stage oncology company prepares to move vopimetostat, its investigational PRMT5 inhibitor, toward potential late-stage development for pancreatic cancer [1].
Azelby brings more than three decades of leadership in the biopharmaceutical industry, with deep expertise in oncology commercialization, corporate strategy, company building, and board governance [1]. The appointment positions the board for the next phase of the company's development as vopimetostat progresses through clinical trials.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.